- Home
- REE vs CYCC Comparison
REE vs CYCC Comparison
Compare REE & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- CYCC
- Stock Information
- Founded
- REE 2011
- CYCC 1992
- Country
- REE Israel
- CYCC Malaysia
- Employees
- REE N/A
- CYCC N/A
- Industry
- REE Auto Manufacturing
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- CYCC Health Care
- Exchange
- REE Nasdaq
- CYCC Nasdaq
- Market Cap
- REE 18.5M
- CYCC 17.5M
- IPO Year
- REE N/A
- CYCC N/A
- Fundamental
- Price
- REE $0.67
- CYCC $7.12
- Analyst Decision
- REE Strong Buy
- CYCC
- Analyst Count
- REE 2
- CYCC 0
- Target Price
- REE $11.75
- CYCC N/A
- AVG Volume (30 Days)
- REE 60.3K
- CYCC 86.9K
- Earning Date
- REE 09-25-2025
- CYCC 08-13-2025
- Dividend Yield
- REE N/A
- CYCC N/A
- EPS Growth
- REE N/A
- CYCC N/A
- EPS
- REE N/A
- CYCC N/A
- Revenue
- REE $183,000.00
- CYCC $10,000.00
- Revenue This Year
- REE $6,661.20
- CYCC $137.21
- Revenue Next Year
- REE $2,240.01
- CYCC N/A
- P/E Ratio
- REE N/A
- CYCC N/A
- Revenue Growth
- REE N/A
- CYCC N/A
- 52 Week Low
- REE $0.53
- CYCC $3.08
- 52 Week High
- REE $11.72
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- REE 42.94
- CYCC 41.06
- Support Level
- REE $0.64
- CYCC $7.30
- Resistance Level
- REE $0.77
- CYCC $8.82
- Average True Range (ATR)
- REE 0.04
- CYCC 0.63
- MACD
- REE -0.00
- CYCC 0.03
- Stochastic Oscillator
- REE 22.50
- CYCC 17.87
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.